Request ConsultationThe FDA is advancing organ on chip technology and other non animal testing methods for drug development. These human relevant models can improve safety testing, disease modeling, and drug development efficiency.
What Are Organs-on-Chips?
Organs-on-chips are systems consisting of engineered or natural miniature tissues grown inside microfluidic chips. The chips are mainly designed to control cell microenvironments and sustain tissue-specific functions to more closely simulate human biological functions. This further integrates advances in tissue engineering and microfabrication, also gaining traction as a next-generation experimental platform to investigate human pathophysiology and the effect of therapeutics in the body.
Microfluidic cell culture devices provide many advantages over macroscopic cell culture, including the necessity of a small cell volume, reduced reagent consumption, real-time and on-chip analysis, automation, flexibility of device design, and direct coupling to downstream analysis systems. Additionally, Multi-Organ Integration also connects multiple chips through microfluidic tubing to study systemic drug metabolism, pharmacokinetics, and organ cross-talk.
Human cell and tissues are cell sources are mainly connected with living primary human cells, endothelial cells, or patient-derived stem cells to match specific genetic backgrounds. Cell-Cell communication also allows porous membrane allows different cell layers to interact and signal back and forth, driving realistic tissue maturation.
Furthermore, human-relevant disease models recreate pathology simulates specific disease states such as asthma, inflammation, or thrombosis due to pathogens, toxins, or genetic changes. Personalized medicine also leverages patient-specific cells to model individual responses to targeted therapies and helps to predict clinical efficacy before actual administration.
Why Drug Development Is Moving Beyond Animal Testing
Limitations of animal models
Animal models are often limited by their struggle to accurately replicate human health and disease due to systemic flaws. These include artificially induced diseases, a lack of genetic diversity in lab animals, models that fail to capture the true origin and progression of the disease, and flawed dosing metrics that do not mimic human exposures.
Human biological differences
Emerging human-first drug discovery methods also focus on human biology by leveraging immune organoids and AI to better simulate immune responses across diverse populations. This approach not only reduces dependence on animal testing but also offers early insights into drug safety and effectiveness, which could ultimately help to shorten development timelines and reduce costs.
Drug-development failures
Physical and biological differences between species lead to discrepancies in preclinical data. Animal models often yield false positives and negatives, resulting in the costly failure of drugs in human trials. Over 90% of drugs deemed safe in animal studies ultimately fail during clinical trials, leading to wasted resources and delayed therapies.
Need for better human predictability
The FDA is now exploring strategies to mitigate and replace animal testing with advanced in vitro systems and modeling. This further accelerates ethical drug development that helps make therapies safer and more effective while reducing animal testing. Implementing this new roadmap positions the FDA as a leader in innovative regulatory science, significantly impacting both patients and the pharmaceutical industry.
How Does Organ-on-Chip Technology Work?
Organ-on-a-chip technology integrates microfluidics, living human cells, and tissue simulation to replicate the three-dimensional structure, mechanical environment, and real-time monitoring of physiological functions in real human organs.
Organ-Chips integrate cell culture with microfluidics to mimic the biological forces of various organ tissues and disease states, such as peristalsis in the intestines, breathing in the lungs, and blood flow in the vascular system. These chips are flexible, thumb-drive-sized devices featuring parallel upper and lower microfluidic channels, each populated with organ-specific cells.
The channels are further separated by a thin, porous membrane, and developing an interface for cell-to-cell communication. This membrane is coated with a tissue-specific extracellular matrix, which further drives tissue maturation.
Concurrently, organ-chips are cultured within a microfluidic platform that automates fluid flow and cyclic mechanical strain, maintaining physiologically relevant conditions in the chip's microenvironment. This setup ensures the cells behave as if they were in their native organ, allowing them to respond to drugs, chemicals, and other substances accordingly.
Researchers can collect data in real time using high-content microscopy imaging, effluent sampling, and various functional measurements. They can also conduct traditional endpoint analyses, such as cytotoxicity assays and immunohistochemistry, coupled with omics-based analyses to identify relevant disease pathways.
Major Types of Organ Chips
The organ-on-a-chip models are developed by leveraging microfluidic technologies thats, making them highly relevant for precise dosing and genetic studies. The different types of organ chips are as follows:
- Liver-on-chip: This model addresses drug failures in preclinical trials due to hepatotoxicity, offering a rapid alternative to animal studies. It supports research on organogenesis, hepatitis B, biomarkers, and therapeutic interventions by co-culturing hepatocytes with Kupffer cells, providing long-term experimental capabilities.
- Heart-on-chip: This is also designed to study heart functions and explores electrical stimulation, cardiac diseases, and the impact of particulate matter. It simulates various conditions like hypoxia and tachycardia, and is used for therapeutic testing, particularly with stem cells.
- Lung-on-chip: These are developed to mimic lung conditions and the effects of smoking on pulmonary diseases. They have shown results comparable to animal studies, emphasizing gene regulation and biomarker discovery, and enable toxicology tests and pulmonary drug delivery evaluations.
- Kidney-on-chip: These are primarily designed with two compartments to mimic the urinary lumen and interstitial space, and leverage rat tubular cells to study nephrotoxicity, drug membrane permeability, and important kidney functions like glucose reabsorption.
- Brain-on-chip: While engineering a full brain structure is challenging, specific functions such as the spinal cord and blood-brain barrier have been replicated. Models differ broadly and include microfluidic and hydrogel-based designs by leveraging techniques such as 3D printing.Gut-on-chip: This chip recreates a controlled gut microenvironment with various human cell types, studying drug pharmacokinetics and host-gut microbiota interactions. It investigates cellular permeability and viral infections.
FDA's New Direction on Non-Animal Testing
Terminology update emphasizes FDA replacing animal tests and animal studies with nonclinical tests and nonclinical studies per the Food and Drug Omnibus Reform Act of 2022 (FDORA). This change does not ban animal testing or lower existing standards by removing the implication that animal studies are the only acceptable method. The direct final rule is set to take effect on February 4, 2027, pending public comments.
The rule aligns with FDORA and does not impose new costs or requirements. A NAMs database has been launched with 25 examples. Related guidance will be issued in December 2025 (mAb primate testing) and March 2026 (broader NAMs guidance).
From an industry perspective, human-derived antibody platforms already comply with the new standards. The public comment period is open, and the rule could be withdrawn due to significant adverse feedback.
Drug safety testing and biological products leverage new Approach Methodologies (NAMs) like developers to use modern, human-centric tools such as human cell-based assays and organs-on-chips. The shift from preclinical to nonclinical reflects diverse testing options, allowing researchers to choose methods that best predict human responses.
The FDA introduced a regulatory acceptance case database with 25 NAM use cases, emphasizing that non-animal alternatives must be validated for regulatory submissions.
Organoids vs Organs-on-Chips vs Animal Models
- Testing Capabilities: Organoids are represented as excellent for localized disease modeling and personalized medicine, while Organ-on-Chip excel in real-time monitoring and pharmacokinetic profiling under continuous fluid flow. Animal Models are vital for assessing systemic toxicity and long-term efficacy.
- Scalability: Organoids have moderate throughput potential but face batch variation challenges. Organ-on-Chip have lower throughput due to complex microfluidic designs, and Animal Models are limited by logistics and regulatory constraints.
- Cost: Organoids require a moderate budget mainly for specialized media. Organ-on-Chip involves high costs from advanced fabrication and fluid systems. Animal Models demand a significant financial investment for animal care and oversight.
- Limitations: Organoids can develop necrotic cores and exhibit genetic drift, while Organ-on-Chip struggle with standardization and drug absorption issues. Animal Models experience poor clinical translation and face ethical concerns.
Overall, organoids and Organ-on-Chip complement each other in biomedical research, with organoids suitable for capturing human tissue characteristics and Organ-on-Chip mimicking organ functions. Addressing their limitations and promoting standardization could further enhance personalized and precision medicine.
How Organ Chips are Changing Drug Discovery
It impacts toxicity testing by predicting safety that identifies organ-specific toxicity, such as liver or kidney damage, early in development, before human or animal testing. Additionally, it further reduces failures by addressing toxic side effects that standard 2D cell cultures or animal models miss due to species differences.
Drug Efficacy can be enhanced by validating treatments under realistic mechanical and fluid flows. Real-time monitoring also tracks cellular responses, biomarker releases, and tissue recovery dynamically over time. It also simulates human ADME leveraging multi-organ chips that connect liver, gut, and kidney chips, and dosing optimization evaluates how a drug breaks down and circulates through interconnected human tissues.
Disease modeling recreates pathology by exposing chips to pathogens or mechanical stress, modeling complex human diseases, rare genetic disorders, and infections. Furthermore, observes how diseases progress and spread across tissue boundaries in a controlled environment and investigates overall mechanisms.
Personalized Medicine Patient-Specific Avatars: Combines microfluidics with patient-derived induced pluripotent stem cells (iPSCs) or biopsies.Customized Treatments: Tests multiple therapies on a chip built from an individual's own cells to find the most effective treatment with the fewest side effects.
Patient-Specific Avatars and Customized Treatments represent the frontier of personalized medicine, combining organ-on-a-chip technology with a patient's genetic material. This approach mitigates trial-and-error prescribing by testing therapies in a lab before they ever reach the patient.
AI and organ-on-chip technology
Integrating AI with Organs-on-Chips shifts microfluidic biological models into intelligent systems that improve preclinical drug development and reduce animal testing.
AI-driven data analytics and prediction-advanced neural networks parse massive streams of multi-omics, imaging, and sensor data from multi-channel chip platforms, mitigating human error while identifying complex pathological patterns. Automated robotic liquid handling and integrated biosensors develop real-time feedback loops, allowing AI to dynamically control experimental workflows, alter chemical gradients, and adjust perfusion rates without manual intervention.
At the same time, it provides predictive simulation and safety, where deep learning models integrate high-throughput screening data with cellular imaging, fluid pressure, and electrical resistance to forecast complex pharmacokinetic and pharmacodynamic outcomes. This real-time biological data feeds into digital replicas of human organs, developing virtual physiological models that simulate long-term patient responses, flag specific toxicities like cardiotoxicity, and isolate therapeutic compounds faster than traditional animal testing.
Companies and Research Ecosystem
Organ-Chip Developers
Emulate, Inc.: It has prominence for its Human Emulation System, offering lung, liver, brain, kidney, and intestine chips to model complex human physiology.
Mimetas B.V.: Known for developing the OrganoPlate® platform, offering high-throughput, 3D tissue culture screening suited for disease modeling and drug testing.
Pharmaceutical Companies
AstraZeneca: A major pharmaceutical player that has deeply integrated Emulate’s organ-on-chip tech into its internal therapeutic areas to evaluate lung and kidney toxicity.
Novartis: A known player that leverages microphysiological systems within its core research and development divisions to evaluate safety profiles for innovative therapeutics.
Biotech Companies
Regeneron Pharmaceuticals: A prominent firm that applies advanced science platforms to test new monoclonal antibodies and target genetic conditions.
BioMarin Pharmaceutical: It prioritizes genetic discoveries and rare diseases, leaning heavily on advanced preclinical human tissue models to accelerate clinical pathways.
Academic Research
Wyss Institute for Biologically Inspired Engineering: The foundational birthplace of modern organ-on-a-chip technology, where the first human lung-on-a-chip was famously engineered.
MESA Institute for Nanotechnology: A leading European academic centre focused on fluidics, micro-system engineering, and advanced human-on-a-chip setups.
Regulatory Agencies
U.S. Food and Drug Administration (FDA): It promotes alternative methods via initiatives like the FDA Modernization Act, collaborating with developers to integrate Organs-on-Chips data into standard regulatory pathways.
European Medicines Agency (EMA): It actively fosters the use of microphysiological systems and 3D human models through its innovation task force to replace, reduce, and refine animal trials.
Different Challenges Hindering Commercial Adoption
- Standardization: The lack of universal standards for materials, dimensions, and fluidics, along with the lack of standard operating procedures, limits reliable data comparison across various laboratories and industries.
- Reproducibility: Variation in biological components and inconsistent manufacturing tolerances make it more challenging to consistently replicate experimental results across different batches and facilities.
- Validation: Platforms must undergo extensive benchmarking against animal models and historical human data to rigorously establish their analytical validity and clinical relevance before being adopted.
- Manufacturing Scale: Transitioning from low-throughput laboratory prototypes to high-volume commercial production necessitates specialized biocompatible materials, cost-effective automation, and strict quality control measures.
- Regulatory Acceptance: Regulatory approval of new platforms by bodies like the FDA and EMA is significantly delayed because of the absence of clear and standardized regulatory guidelines.
- Workflow Integration: Integrating new systems into existing pharmaceutical workflows necessitates seamless compatibility with current robotic hardware and data pipelines, which necessitates significant investment and staff retraining.
Future of Preclinical Drug Testing
Regulatory modernization resulting from the U.S. FDA Modernization Act 2.0 eliminated mandatory animal testing, which enables researchers to use human-relevant data for investigational new drug applications while global regulators actively lower rodent and primate usage.
Advanced microphysiological systems representing lab-grown organoids, 3D bioprinting, and Organ-on-a-Chip microfluidic devices replicate dynamic human organ functions and frequently outperform animal models in predicting human-specific toxicities.
Personalized clinical screening leveraging donor-derived induced pluripotent stem cells (iPSCs) allows for patient-specific drug efficacy and toxicity testing, which efficiently reduces the historical clinical failure rate in drug development.
AI-driven preclinical insights lead to advanced machine learning platforms and digital twins that screen massive compound libraries to predict ADMET properties, simulate complex clinical trials, and optimize dosing regimens to reduce development timelines.
Overall, the future of preclinical drug testing is shifting toward human-relevant technologies such as organ-on-a-chip, organoids, and AI. These innovations can reduce animal testing, improve safety predictions, and accelerate drug development.
About the Authors
Aditi Shivarkar
Aditi, Vice President at Precedence Research, brings over 15 years of expertise at the intersection of technology, innovation, and strategic market intelligence. A visionary leader, she excels in transforming complex data into actionable insights that empower businesses to thrive in dynamic markets. Her leadership combines analytical precision with forward-thinking strategy, driving measurable growth, competitive advantage, and lasting impact across industries.
Aman Singh
Aman Singh with over 13 years of progressive expertise at the intersection of technology, innovation, and strategic market intelligence, Aman Singh stands as a leading authority in global research and consulting. Renowned for his ability to decode complex technological transformations, he provides forward-looking insights that drive strategic decision-making. At Precedence Research, Aman leads a global team of analysts, fostering a culture of research excellence, analytical precision, and visionary thinking.
Piyush Pawar
Piyush Pawar brings over a decade of experience as Senior Manager, Sales & Business Growth, acting as the essential liaison between clients and our research authors. He translates sophisticated insights into practical strategies, ensuring client objectives are met with precision. Piyush’s expertise in market dynamics, relationship management, and strategic execution enables organizations to leverage intelligence effectively, achieving operational excellence, innovation, and sustained growth.